Literature DB >> 26992110

Is the prevalence of colonic neuroendocrine tumors increased in patients with inflammatory bowel disease?

Lauranne A A P Derikx1, Wouter-Michiel A M Vierdag1, Wietske Kievit2, Steven Bosch2, Frank Hoentjen1, Iris D Nagtegaal3.   

Abstract

Inflammatory bowel disease (IBD) patients may bear an increased neuroendocrine tumor (NET) risk. These tumors are mostly reported as coincidental findings during surgery. We aimed to determine the prevalence of colonic NET in a Dutch nationwide IBD cohort and calculate the prevalence rate ratios (PRR) compared with the general Dutch population. Our second aim was to investigate whether a high bowel surgery rate in IBD could result in a high PRR for NET. The Dutch Pathology Registry (PALGA) was searched to identify all IBD patients with colonic NET in The Netherlands between 1991 and 2011. We determined the prevalence and PRR of colonic NET in a 20-year period. For our second aim, we compared NET prevalence in colonic resection specimens between IBD cases and non-IBD controls (diverticulitis and ischemia). We identified 51 IBD patients who developed colonic NET resulting in a prevalence of 60.4-89.3 per 100,000 patients in a 20-year period with a PRR of 2.8-4.1. However, adjusted for resection type, sex and age, a higher NET prevalence was shown in diverticulitis (OR 5.52, 95% CI 3.47-8.78) and ischemia (OR 1.97, 95% CI 1.09-3.58) compared with IBD. Our key finding is that NET are more prevalent in IBD patients compared with the general population (PRR 2.8-4.1). This might be attributed to a high rate of incidental NET as IBD patients frequently undergo intestinal surgery. A lower adjusted NET prevalence in colonic resection specimens for IBD compared to ischemia and diverticulitis supports this hypothesis.
© 2016 UICC.

Entities:  

Keywords:  cancer risk; inflammation; inflammatory bowel disease; neuroendocrine tumor

Mesh:

Year:  2016        PMID: 26992110     DOI: 10.1002/ijc.30096

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Casting a Wider NET: Is It Crohn's or Is It Neuroendocrine Tumor?

Authors:  Yejoo Jeon; David Leung; Claire A Lis; Hanlin L Wang; Corinne Deurdulian; Mark Mandelkern; Jonathan D Kaunitz
Journal:  Dig Dis Sci       Date:  2021-03-30       Impact factor: 3.199

2.  Epidemiological, clinical and endoscopic characteristics of colorectal neuroendocrine neoplasms: a population-based study in the Netherlands.

Authors:  Ankie Reumkens; Prapto Sastrowijoto; Heike I Grabsch; Danny Goudkade; Chantal le Clercq; Minke Bakker; Eric Keulen; Rogier de Ridder; Wouter W de Herder; Bjorn Winkens; Silvia Sanduleanu; Judith de Vos-Geelen; Ad Masclee
Journal:  Endosc Int Open       Date:  2022-07-15

3.  Childhood neuroendocrine tumours: a descriptive study revealing clues for genetic predisposition.

Authors:  I J Diets; I D Nagtegaal; J Loeffen; I de Blaauw; E Waanders; N Hoogerbrugge; M C J Jongmans
Journal:  Br J Cancer       Date:  2016-12-13       Impact factor: 7.640

Review 4.  From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?

Authors:  Giovanni Vitale; Alessandra Dicitore; Luigi Barrea; Emilia Sbardella; Paola Razzore; Severo Campione; Antongiulio Faggiano; Annamaria Colao; Manuela Albertelli; Barbara Altieri; Filomena Bottiglieri; Federica De Cicco; Sergio Di Molfetta; Giuseppe Fanciulli; Tiziana Feola; Diego Ferone; Francesco Ferraù; Marco Gallo; Elisa Giannetta; Federica Grillo; Erika Grossrubatscher; Elia Guadagno; Valentina Guarnotta; Andrea M Isidori; Andrea Lania; Andrea Lenzi; Fabio Lo Calzo; Pasquale Malandrino; Erika Messina; Roberta Modica; Giovanna Muscogiuri; Luca Pes; Genoveffa Pizza; Riccardo Pofi; Giulia Puliani; Carmen Rainone; Laura Rizza; Manila Rubino; Rosa Maria Ruggieri; Franz Sesti; Mary Anna Venneri; Maria Chiara Zatelli
Journal:  Rev Endocr Metab Disord       Date:  2020-09-15       Impact factor: 9.306

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.